Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Nov-Dec;31(6):555-558.
doi: 10.4103/ijn.IJN_429_20. Epub 2021 Apr 7.

Continuous Hemodiafiltration with the oXiris Filter Ameliorates Cytokine Storm and Induces Rapid Clinical Improvement in COVID-19 - A Case Report

Valentine A Lobo  1 , Arati Lokhande  2 , Vipul Chakurkar  1 , Pradeep M D'Costa  2
Affiliations
Case Reports

Continuous Hemodiafiltration with the oXiris Filter Ameliorates Cytokine Storm and Induces Rapid Clinical Improvement in COVID-19 - A Case Report

Valentine A Lobo et al. Indian J Nephrol. 2021 Nov-Dec.

Abstract

Delayed interferon secretion and cytokine dysregulation are responsible for the life-threatening acute respiratory distress syndrome (ARDS), multiorgan dysfunction and shock in COVID 19, which closely resembles secondary hemophagocytic lymphohistiocytosis (sHLH). IL-6, a marker of hypercytokinemia in patients with COVID-19 is positively correlated with disease severity, development and progression of ARDS, and mortality. Therapy to either reduce IL-6 or inhibit its action with either non-specific inhibitors of inflammation like dexamthasone or Toclizumab a specific inhibitor of IL-6 has produced decrease in mortality. We describe a novel method of treatment in a patient with multiorgan involvement in COVID 19, using the oXiris hemofilter which delivers renal replacement therapy while also reducing cytokines like IL-6.

Keywords: COVID cytokine storm; interleukin 6; oXiris hemodiafiltration acute kidney injury.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

References

    1. Maggo S, Dhull P, Dubey AP, Brashier D, Karan A, Singh NK, et al. Cytokine storm syndrome in COVID-19: Diagnosis and management strategies. Int J Health Sci Res. 2020;10:140–8.
    1. Mehta Y, Dixit SB, Zirpe KG, Ansari AS. Cytokine storm in novel coronavirus disease (COVID-19): Expert management considerations. Indian J Crit Care Med. 2020;24:429–34. - PMC - PubMed
    1. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the 'Cytokine Storm' in COVID-19. J Infect. 2020;80:607–13. - PMC - PubMed
    1. Michot JM, Albiges L, Chaput N, Saada V, Pommeret F, Griscelli F, et al. Tocilizumab, an anti-IL6 receptor antibody, to treat COVID-19-related respiratory failure: A case report. Ann Oncol. 2020;31:961–4. - PMC - PubMed
    1. RECOVERY Collaborative Group. Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in hospitalized patients with COVID-19 – Preliminary report. N Engl J Med. 2020 doi: 10.1056/NEJMoa2021436. - PMC - PubMed

Publication types